marijuana stocks

SinglePoint Analyst Report: Mobilizing the Medical Marijuana Industry Issued by Small Cap IR

 NEW YORK, Jan. 29, 2015 /PRNewswire/ — Analyst report issued by Small Cap IR. SinglePoint Inc. (OTC Other: SING) based in Seattle, WA recently announced the finalization of the acquisition of GreenStar and the product roll out from this newly acquired brand. SinglePoint focuses their efforts on providing mobile payment services throughout different industries and most recently the medical and recreational marijuana industry. SinglePoint will be introducing other products alongside their mobile payments technology and these include both traditional and smokeless tobacco products ranging from electronic cigarettes, vape pens and, contingent on the trade embargo being lifted, Cuban cigars.

The company has not reported any significant earnings in the last quarter, but it appears that the pieces are finally falling into place and profitable news may be on the way.

For a more detailed research report with analyst comments and recommendation on SinglePoint Inc. please follow the link. There is no cost obligation required to view analyst brief:

https://bit.ly/-SING-AnalystReport

We make the connection between sophisticated investors and high quality small cap companies. An issuer of reports written by chartered financial analysts (CFA’s) who provide a straightforward assessment of the profiled company and have pledged to remain free of influence when writing research reports. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.

For more information and services provided beyond this release please use contact information provided below.

Forward-Looking Disclaimer

This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.

Compliance Procedure

Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.

A full disclaimer can be found by viewing the analyst report.

If you wish to have a company covered in more detail by our team, or wish to learn more about our services, please contact us at editor@smallcapir.com. For any urgent concerns or inquiries please contact us at editor@smallcapir.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Contact: editor@smallcapir.com 

To view the original version on PR Newswire, visit:https://www.prnewswire.com/news-releases/singlepoint-analyst-report-mobilizing-the-medical-marijuana-industry-issued-by-small-cap-ir-300027530.html


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
1 comment
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Curaleaf Holdings, Inc. (CURLF) Announces Launch of Adult-Use Cannabis Sales at Stamford, CT Dispensary

Curaleaf Announces Launch of Adult-Use Cannabis Sales at Stamford, CT Dispensary Curaleaf…

Planet 13 Holdings Inc. (PLNHF) Announces a Partnership with Curaleaf’s Select Brand to Open Select Shop

Planet 13 Announces a Partnership with Curaleaf’s Select Brand to Open Select…

Cara Therapeutics (CARA) Initiates Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA™

Enteris BioPharma’s “Feasibility-to-Licensing” Partner, Cara Therapeutics, Initiates Phase 2 Trial of Peptelligence®-Engineered…

GW Pharmaceuticals plc (GWPH) to Report Second Quarter Financial Results and Host Conference Call on 8 May, 2018

GW Pharmaceuticals to Report Second Quarter Financial Results and Host Conference Call…